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Abstract
Multiple sclerosis (MS) is a complex disease with many 
different immune cells involved in its pathogenesis, and 
in particular T cells as the most recognized cell type. 
Recently, the innate immune system has also been re-
searched for its effect on the disease. Hence, cells of 
the immune system play vital roles in either ameliorat-
ing or exacerbating the disease. The genetic and envi-
ronmental factors, as well as the etiology and patho-
genesis are of utmost importance for the development 
of MS. An insight into the roles play by T cells, B cells, 
natural killer cells, and dendritic cells in MS and the 
animal model experimental autoimmune encephalomy-
elitis, will be presented. Understanding the mechanisms 
of action for current therapeutic modalities should help 
developing new therapeutic tools to treat this disease 
and other autoimmune diseases. 
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The role played by various immune cells in 
either ameliorating or exacerbating multiple sclerosis is 
discussed.
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INTRODUCTION
Recent developments in multiple sclerosis (MS) research 
have been staggering, including numerous new therapies 
either approved or at the brink of  approval, new oral 
therapies and leaps made in genetics. This article will 
focus on the role that immune cells play in MS, and their 
involvement in mediating the effects of  drugs used to 
treat relapsing-remitting (RR) MS patients.
GENERAL FEATURES OF MULTIPLE 
SCLEROSIS
The basic pathology of  MS was recognized almost 150 
years ago by Charcot who described a disease caused by 
sclerotic plaques in the central nervous system (CNS) of  
those affected[1]. There were other reports describing the 
pathology before this time, but failed to recognize it as a 
distinct disease[2]. It is reasonable to believe that MS has 
been prevalent also before these descriptions, as the dis-
ease often arises early in life[3]. Today, we know that MS is 
a chronic inflammatory, autoimmune, demyelinating and 
degenerative disease of  the CNS[4]. Substantial discover-
ies have been made regarding its therapeutics, pathogen-
esis and genetics. Yet, there is no cure and no recognized 
definite cause, be it genetic, microbial or environmental. 
Although no definite cause of  MS has yet been identified, 
substantial amounts of  research point to a dual multifac-
torial influence of  both genetics and environmental ele-
ments contributing to the development of  the disease[5,6]. 
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Genetic factors
The genetic component was first described after family 
studies were performed, with a family recurrence rate of  
about 20%-33%, and about 10-12 fold risk increase in 
first degree and three folds in second degree relatives[7,8]. 
For siblings or children of  patients with MS, the overall 
risk was estimated to be 3%-5%[9], but twin studies show a 
higher risk (25%) if  the sibling is a monozygotic twin[10,11]. 
The first risk allele to be identified was the human 
leukocyte antigen (HLA) class Ⅱ haplotype HLA-DRB 
1501 in the early 1970’s[12], which is also the allele with the 
strongest association with the disease[13]. The road to dis-
covering additional alleles was complicated and hampered 
by insufficient methods[4,14]. In recent years large genome 
wide association studies (GWAS) using single nucleo-
tide polymorphisms and comparing diseased to healthy 
individuals have made it possible to identify numerous 
alleles associated with MS with sufficient power and 
significance, most of  these with low to modest MS risk 
association[5,15]. Researchers with the help from a huge 
GWAS consortium[13] identified over 50 susceptible loci, 
many of  which are associated with the immune system, 
including genes encoding receptors for interleukin (IL)-2 
and IL-7[15]. Other genes important for cytokine pathways 
include CXCR5, IL-12A, IL-12β, IL-12Rβ1 among oth-
ers associated with the cytokine tumor necrosis factor α, 
as well as genes associated with co-stimulatory molecules 
such as CD80, CD86, CD37 were also described. GWAS 
studies have even identified risk association with genes 
that are important for current and new MS therapies in-
cluding IL-2Rα (daclizumab) and VCAM1 (natalizumab), 
as well as genes related to environmental risk factor vita-
min D3[13]. Such knowledge while adding new information 
supports much of  what is known about MS pathogenesis. 
Still, further research into these risk alleles is needed to 
improve our understanding of  their associations with the 
disease.
Environmental factors
While family studies support a genetic association, they 
also show that genetics alone are not enough to develop 
MS, as shown by homozygous twins not both acquiring 
disease, even though one of  them is diagnosed with MS. 
Other information supporting environmental effects 
include the geographic increase of  MS with increasing 
latitude[16], and how individuals migrating from low-risk 
to high-risk areas acquire higher susceptibility if  the mi-
gration occurs during childhood. Hence, the incidence of  
developing MS correlates with the risk in areas of  child-
hood residence[4]. Additionally, studies have shown risk 
association during months of  birth as spring births have 
higher risk of  MS than autumn births[17].
Several environmental factors have been investigated. 
One hypothesis is that vitamin D3 deficiency increases 
the risk of  MS, as increased latitude is also correlated 
with lower blood vitamin D3 levels. For instance, ecologi-
cal studies showed the amount of  exposure to sunlight 
was inversely correlated with the risk of  MS, both by 
regional distribution and association with altitude, as well 
as by individual exposure to sunlight[18]. Sunlight is the 
main source of  human vitamin D3 through conversion 
of  7-dehydrocholesterol to previtamin D3 in the skin, 
and through further metabolic steps to active hormone 
1,25-Dihydroxyvitamin D3[19]. It was also shown how 
vitamin D3 intake may reduce the risk of  MS because 
of  latitude dependent deficiency, for instance in com-
munities which consume higher amounts of  vitamin D3 
rich fish[20]. These studies also point out the difficulties 
of  such concepts, as confounding factors may be quite 
prevalent. There is also association with the experimental 
autoimmune encephalomyelitis (EAE) model, an animal 
model for MS, as dosing of  1,25(OH)2D3 prevented the 
disease[21,22]. These effects may be induced by vitamin D3 
on the adaptive immune system not yet fully understood. 
Definite effects of  supplementing patients with vitamin 
D3 have not yet been shown, but some studies indicate 
that serum concentrations of  vitamin D3 may affect dis-
ease severity[19]. However, this field is quickly developing, 
and is being investigated for possible future prospects, 
for instance in preventing MS[23].
Another risk factor with strong association to MS is 
Epstein Barr virus (EBV) infection[24,25]. A major finding 
was that individuals who were seronegative for EBV had 
very low, almost no risk of  acquiring MS when compared 
to seropositive individuals[24]. However, those patients 
who at some point infected with EBV are not neces-
sarily at risk of  developing MS[6]. Further, there was an 
increased risk of  MS if  a history of  infectious mononu-
cleosis and a temporal increase of  EBV antibodies serum 
titers were present[26], and that MS patients were more 
often infected with EBV at later ages when compared 
to controls[27]. It has been hypothesized that EBV may 
mimic myelin basic protein (MBP) pathogenic antigens 
by presentation on HLA-DRB1*1501, hence, providing 
links to both environmental and genetic risk factors[28]. 
Although the association with MS is well investigated, the 
role of  EBV in its pathology remains uncertain. Howev-
er, EBV infection and mononucleosis as a priming or ini-
tiating factors for developing MS are seemingly likely[24]. 
Finally, many other factors have shown association with 
increased MS risk but are in need of  further research to 
be conclusive. These include cigarette smoking, a diet 
rich in saturated but low in polyunsaturated fats, sex 
hormones, and socioeconomic status, among others[18,29]. 
Viruses other than EBV have also been implicated in the 
etiology of  MS[30].
CLINICAL OBSERVATIONS
Natural history
Patients with MS show a wide variety of  symptoms 
caused by lesions in the CNS affecting motor, sensory, vi-
sual or even autonomic functions. Lesions appear mainly 
in the white matter, but also appear in the grey matter. 
Hence, symptoms show great heterogeneity in both inter- 
and intra-individually ranging from slight tingling in the 
fingers to extreme fatigue or complete monocular loss 
of  sight, depending on the lesion(s) localization[4]. Com-
28 August 20, 2014|Volume 4|Issue 3|WJEM|www.wjgnet.com
Høglund RA et al . Multiple sclerosis and the role of immune cells 
monly, the patients present with a clinically isolated syn-
drome (CIS), followed by serial sub-acute relapses with 
varying time intervals. The number of  annual relapses 
and time intervals between them varies among patients, 
but more than 1.5 relapses/year is a rare occasion[4]. Not 
all patients have subsequent disease activity after a single 
CIS, but risk of  another episode is increased if  white 
matter lesions are detected by MRI[31]. Between relapses 
the patients revert spontaneously to normal or near nor-
mal neurological function. This clinical subtype of  MS 
is referred to as RR MS, and most patients are present 
with this form of  MS[30]. The clinical course may later 
convert to a more progressive stage in about 65% of  the 
patients, with fewer or no relapse activity and increasing 
irreversible disability. Patients have a mean age of  about 
40 years when they enter this stage, referred to as second-
ary progressive (SP) MS[32,33]. A minority of  patients (about 
10%-15%) may present with progressive disability and no 
relapsing activity, this is called primary progressive (PP) 
MS[34]. This subtype usually has a later onset than RRMS, 
at a mean age of  around 40 years[33].
Patients with MS experience decades of  disease 
and eventual progression. Due to many complications 
which occur alongside increased disability, the average 
life expectancy is reduced by about 5-10 years, and has a 
median time of  30 years between onset and death[35]. It 
remains to be seen whether current or future therapeutic 
methods may extend the time until irreversible disability 
occurs. 
ROLE OF IMMUNE CELLS IN MS
The blood brain barrier
An important finding in MS lesion is the disruption of  
the blood brain barrier (BBB), and hence a basic under-
standing of  this barrier is essential to understand the 
pathogenesis of  the disease[36]. The BBB is a functional 
and anatomical barrier separating the blood from neurons 
in the CNS. It consists of  both the vascular wall, CNS as-
trocytes covering these with glia limitans, and the perivas-
cular space in between[37]. The BBB has several important 
functions vital for the brain to function properly, includ-
ing maintenance of  proper ionic concentrations through 
dynamic regulation. The BBB may be viewed as a concept 
rather than an actual barrier. Even though the word barri-
er has a certain static ring to it, the BBB is rather dynamic 
allowing for instance immunological surveillance[38,39]. Le-
sions occur when leukocytes migrate into the brain and 
inflammation ensues. This is a two-step process, involv-
ing an initial migration across post-capillary venules into 
perivascular space, and further migration through the glia 
limitans into the brain parenchyma[37]. The perivascular 
space allows normal immunosurveillance by monocytes, 
as this space also serves as the brains’ lymphatic drain-
age[37]. There are at least two additional routes for leuko-
cytes to enter the CNS, as shown by accumulation of  im-
mune cells at these sites in animal models, which include 
the blood-cerebrospinal fluid (CSF) barrier in the choroid 
plexus, and through meningeal arteries[39].
Role of T cells
The role of  T cells has always been considered central in 
MS pathogenesis, much due to the experimental animal 
model EAE, but also due to the strong genetic associa-
tion with HLA class Ⅱ genes[5]. EAE is a widely used 
animal model for MS, and is induced by immunizing mice 
or other rodents with myelin peptides, or by adoptively 
transferring myelin-reactive T-cells[6]. Hence, they cause 
a T cell mediated acute autoimmune reaction against my-
elin in the rodents CNS, with signs and symptoms that 
are similar to those seen in MS. The cellular pathogenesis 
of  MS is however, more complicated than this[40]. For a 
long time auto-reactive CD4+ T cells secreting interferon-
gamma (IFN-γ), were thought to be the main mediators 
of  the inflammation causing MS lesions[4]. Further re-
search suggests numerous other cell types and cell subsets 
are also involved, with key roles assigned to T helper 17 
(Th17) cells[41]. These T cells secrete the pro-inflammato-
ry cytokines IL-17, IL-6 and are regulated by IL-23[42,43]. 
It is commonly believed that disease occurs when these 
inflammatory cells and/or other cell types become de-
regulated and a transition from physiological surveillance 
to a pathological immune response occurs[4,30]. 
Since EAE is considered a model of  acute inflam-
mation, it has been used to explore what cells are impor-
tant for this process. It was shown in mice with EAE 
that CD4+ Th17 cells are necessary to develop EAE[44]. 
Studies of  lesions from MS patients confirmed an over-
whelming presence of  CD4+ cells secreting IL-17 in 
active lesions. However, in MS lesions both CD4+ and 
CD8+ cells express IL-17[45]. Chemokine receptor CCR6 
expressed on Th17 cells facilitates transport through 
the choroid plexus into the CSF and perivascular space 
by interacting with CCL20/MIP-3α expressed on en-
dothelium[46]. Th17 cells may also produce GM-CSF 
promoted by resident antigen presenting cells (APCs) 
secreting IL-23, which then initiates a positive feedback 
loop as the same APCs are stimulated by GM-CSF[30,47,48]. 
Th17 cells may further increase permeability of  the BBB 
by disrupting the endothelial tight junctions due to the 
secretion of  IL-17 and IL-22, and through interactions 
with endothelium allowing further attraction of  CD4+ 
subsets as well as other immune cells. Consequently, initi-
ating pathological cascade of  inflammation, perivascular 
infiltrates and damage to neurons and glia cells[30,45]. One 
identified damaging molecule is Granzyme B secreted 
by the same Th17 cells[49]. However, to gain access into 
the parenchyma, the cells must traverse the glia limitans. 
This is thought to be mediated by perivascular APCs and 
macrophages secreting matrix metalloproteinases (MMP) 
2 and MMP-9 which are gelatinases able to cleave dystro-
glycan, a transmembrane receptor anchoring astrocytes 
end feet to the parenchymal basement membrane. When 
mice were knocked down for MMP-2 and MMP-9, they 
became resistant to EAE as T-cells became trapped in 
perivascular space[50]. In summary, this cascade may be 
viewed as a stepwise model, with an initial attraction and 
migration of  Th17 cells into the CSF and perivascular 
spaces, and later increased permeability of  the BBB al-
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be due to migration of  the same clones from blood into 
the CSF, plausibly using CCR5 or CCR6 for entry (Table 
1). When these cells were activated, all chemokine recep-
tors expression with the exception of  CCR4 was mark-
edly reduced. The migration pattern corresponded well 
with the expression of  receptors observed, with reduced 
migration observed when receptors were reduced or no 
longer expressed. Similarly after activation, migration 
towards chemokines was less robust. These observations 
support the hypothesis of  diminished effects of  GA due 
to inflammation and premature activation of  GA-reactive 
cells. As migration into the CNS is a necessary step of  
the bystander suppression hypothesis[24], knowledge of  
how these cells migrate into the CNS is important in or-
der to possibly enhance the effectiveness of  this drug.
These results could in part explain why aggressive 
immunosuppression followed by maintenance therapy is 
very effective. Such combination therapy is relatively new 
to MS treatment, but has been used in other autoimmune 
diseases. Inspired by this, researchers applied combination 
therapies which resulted in a better outcome for RRMS 
patients. Several combinations have been tested, some 
show more promise than others. It was for instance de-
scribed how patients treated with a short induction of  mi-
toxantrone followed by longer term GA therapy showed a 
reduction in new relapses compared to GA alone, as well 
promising results regarding gadolinium enhanced lesion 
load[54-57]. This suggests possible synergistic effects among 
these drugs. Mitoxantrone is a powerful immunosuppres-
lowing additional inflammatory cells access, and later 
a complete disruption of  the BBB with damage to the 
CNS occurs, resulting in active lesions and potential 
clinical exacerbation of  the disease[25,30]. 
Although our understanding of  how inflammation 
may be initiated has increased with the advent of  the 
Th17 hypothesis, much remains to be discovered of  
how T cells and other cell types are recruited into the 
CNS during inflammation. It is known that chemokines 
are important for recruiting these cells across the BBB. 
Chemokines are classified into subfamilies, consisting of  
CXC, CC, C and CX3C. While some are constitutively 
expressed, others are up-regulated during inflamma-
tion[51]. In MS lesions, chemokines expressed on post-
capillary venule endothelial walls and bind chemokine 
receptors expressed on T cells, allowing extravasation. 
Chemokine concentration gradients in tissues allow the 
cells to be further guided towards the sites of  inflamma-
tion[52].
We explored the role of  chemokine receptors expres-
sion, which include CCR1, CCR2, CCR3, CCR4, CCR5, 
CCR6, CCR7, CCR9, CCR10, CXCR1, CXCR3, CXCR4, 
CXCR5 and CXCR6 on four T cell clones isolated from 
the blood or CSF of  MS patient who was treated with 
the drug glatiramer acetate (GA). We observed that only 
four chemokine receptors warranted further study. These 
were CCR4, CCR5, CCR6 and CXCR3[53]. The fact that 
all four clones from both peripheral blood and CSF ex-
pressed similar patterns of  chemokine receptors could 
  Receptor
  
Main role Ligands CD4+ subsets PBL-74 PBL-78 CSF-25 CSF-26
Th1 Th2 Naive Unact Act Unact Act Unact Act Unact Act
  CXC family
     CXCR1 I CXCL6, CXCL7, CXCL8
     CXCR2 I CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, 
CXCL7, CXCL8
     CXCR3 I  CXCL9, CXCL10, CXCL11 H H M H M H M H L
     CXCR4 C CXCL12 H
     CXCR5 C CXCL13 M
     CXCR6 I CXCL16
     CXCR7 D CXCL11, CXCL12
  CC family
     CCR1 I CCL3, CCL5, CCL7, CCL8, CCL15, CCL16, 
CCL23
M
     CCR2 I CCL2, CCL7, CCL8, CCL13, CCL16 H H
     CCR3 I CCL5 ,CCL7, CCL11, CCL13, CCL15, CCL24, 
CCL26, CCL28
H
     CCR4 D CCL17, CCL22 H H H H M H H L
     CCR5 I CCL3, CCL4, CCL5, CCL8, CCL11, CCL14, 
CCL16
H H M L H M
     CCR6 D CCL20 M M L
     CCR7 C CCL19, CCL21 H
     CCR8 I CCL1, CCL16 H
     CCR9 D CCL25,
     CCR10 I CCL27, CCL28 L L
  Other
     XCR1 I XCL1, XCL2
     CX3CR1 D CX3CL1
Table 1  Chemokines receptor expression on T cells and T cell clones isolated from MS patient
Data adapted from Høglund et al[53], Maghazachi[90], Zlotnik et al[117] and Sallusto et al[118] . I: Inflammatory; C: Constitutive; D: Dual activities; Unact: Unacti-
vated; Act: Activated; PBL: Peripheral blood lymphocytes; CSF: Cerebrospinal fluid. H: High expression; M: Medium expression; L: Low expression.
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sive drug that is approved for treatment of  RRMS and 
secondary progressive MS (SPMS) in the United States. By 
suppressing inflammation induced by autoreactive T cells 
such as Th17 and/or Th1, this drug may pave the way for 
GA-reactive cell migration into the CNS upon reconstitu-
tion of  the immune system. This way, the cells may medi-
ate their bystander suppression without being impeded by 
an inflammatory environment. However, while initial stud-
ies of  this showed important clinical efficacy, further stud-
ies are warranted in order to determine whether this treat-
ment regimen is better suited than newer therapies such as 
alemtuzumab and other future immunomodulators. 
The presence of  inflammatory T cells in perivascular 
space and parenchyma triggers recruitment of  more T 
cells, as well as B cells, dendritic cells, microglia and natu-
ral killer (NK) cells. The cytokines secreted may by them-
selves cause damage to the surrounding tissues[58]. Com-
plement depositions, opsonization and local activation 
of  microglia and macrophages causing demyelination[59], 
and neuronal cell death are few examples of  the effects 
of  cytokines[60]. Axonal damage is also present[61,62], and 
the degree of  this was associated with abundance of  
microglia and CD8+ T cells[63]. Clonally expanded CD8+ 
T cells are present usually at the lesion edge, as well as in 
the perivascular infiltrates, indicating a specific antigen 
response and also possibly responsible for damages to 
neurons through cell dependent cytotoxicity[64-67]. It was 
also demonstrated that clonal γδ T cells are present in MS 
lesions[68]. When the lesion acute phase is over, removal 
of  cellular debris starts, and simultaneously remyelination 
occurs within the MS plaque. A minority of  the patients 
(about 20%) show more abundant remyelination[69].
In addition, a study showed that MS patients had a 
significant loss of  effector function in the regulatory 
CD4+CD25+ subset of  T cells (Treg), when compared 
to healthy individuals[70]. Another study showed reduced 
frequency of  this subset in general as well as reduced ex-
pression of  transcription factor FOXP3[71]. Although cir-
culating numbers may be the same in patients and healthy 
individuals, the suppressive potential of  Treg cells in MS 
patients was reduced[72]. Interestingly, these T cells were 
also able to produce IL-17 when stimulated with APCs 
in the presence of  IL-2 and IL-15[73], but retained their 
suppressive abilities dependent on the surrounding cyto-
kine environment[74]. Although this regulatory subset may 
inhibit auto reactive T cells, it is not certain where such 
inhibition may occur[41].
Finally, it may be that MS is not initially caused by the 
adaptive immune system at all, but rather as a response to 
an intrinsic CNS neurodegeneration, indicating that in-
flammation may follow initial axonal degeneration caused 
by a currently unknown factor. This is supported by the 
fact that progression of  disease is mainly caused by the 
amount of  lost neurons[30]. In addition, there seems to 
be a correlation between age at onset than initial clinical 
course on the disease progression[33]. 
Role of B cells 
The most obvious argument for B cells being involved 
in MS pathogenesis is the presence of  immunoglobulins 
such as immunoglobulin G1 in the CSF, as detected by 
isoelectric focusing or gel electrophoresis in as many 
as 95% of  diagnosed patients. Although myelin reac-
tive antibodies have been detected, their relevance is not 
certain[25], much like the role of  antigens. In MS lesions, 
there have been findings of  both immunoglobulin and 
complement which may suggest a pathogenic role[75,76]. 
Additionally, B lymphoid follicles, T cells and APCs were 
identified in the meninges of  patients at later stages of  
MS (SPMS but not PPMS)[76,77]. B cells may contribute to 
the pathology through antigen presentation, cell interac-
tions or production of  immunoglobulins from plasma 
cells, although B cell activity may represent a response 
to the autoimmune reaction, rather than to a primary in-
ducer[25].
In EAE, the antigens responsible for the disease have 
been described. By immunizing the animal with myelin 
proteins such as MBP, proteolipid protein or myelin 
oligodendrocyte glycoprotein (MOG), disease can be in-
duced[78]. In humans, such common antigens remain un-
known in spite of  several attempts to identify them[25,30]. 
Several candidate antigens are being or have been inves-
tigated, but no single candidate has been targeted as the 
one responsible. Myelin or peptides derived from myelin 
were thought to be good candidates due to the similarity 
between EAE and MS, but the responses to these anti-
gens have proven to be unspecific and may suggest that 
several antigens are involved and/or an extensive epitope 
spreading occurring after initiation of  the disease[30,41,79]. 
One recently suggested antigen is αβ-crystallin, which 
contrary to previous candidates is not present in human 
myelin, but rather is detected in early active MS lesions, 
and patients have antibodies against it in their CSF[6]. 
When the gene encoding αβ-crystallin was knocked 
down in mice, a more intense inflammatory EAE with 
higher cytokine load occurred[80]. This suggests a protec-
tive role that may be disrupted by a pathogenic immune 
response. Another candidate not directly associated with 
myelin is neurofascin, expressed on neuronal axons. As 
antibodies have been detected in patients with MS, this 
may contribute to axonal damage[81].
Role of NK cells
NK cells are large granular lymphocytes that possess the 
ability to spontaneously lyse target cells without a prior 
sensitization[82]. NK cells also have immunoregulatory 
features, including secretion of  cytokines, chemokines 
and cell to cell contact[83,84]. Functionally, these cells are 
important in immune responses to viral infections as well 
as controlling tumor growths[85,86]. The activities of  these 
cells are regulated by activating and inhibitory receptors, 
which by intracellular integration of  challenges and inhi-
bitions determine the cell course of  action[87]. NK cells 
recognize and are activated by cells that are in distress by 
detecting stress induced ligands on target cells through 
natural cytotoxicity receptors, such as NKp30, NKp44, 
or NKp46, and the C-type lectin receptor NKG2D, 
among others[87,88]. In healthy cells however, activating 
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factors are held in equilibrium by inhibiting signals. NK 
cells express numerous receptors that inhibit activation, 
including members of  the killer-cell immunoglobulin-like 
receptor (KIR) family that interact with HLA-I molecules 
and CD94-NKG2A that interact with HLA-E. In the ab-
sence of  these “self ” ligands, NK cells are activated and 
consequently, kill target cells[89].
In human blood, NK cells constitute about 2% to 
18% of  the total circulating lymphocytes[90,91], and can 
be classified into subsets based on expression of  surface 
receptors. CD16+CD56- constitute about 85%-90% of  
circulating NK cells, are highly cytotoxic but produce 
little cytokines, while CD16-CD56+ cells are less cytotoxic 
but effective cytokine producers[92]. NK cells may also 
be classified based on their cytokine expression. Similar 
to Th1/Th2 subsets, these cells were divided into NK1 
expressing IFN-γ, or NK2 expressing IL-5 and IL-13[93]. 
Further research divided these NK cells into even smaller 
subsets, recognized as NK22 secreting IL-22 and found 
in lymphoid tissues of  the gastrointestinal tract[94], or 
NK17/NK1 cells secreting IL-17 and IFN-γ when stimu-
lated with IL-2[95]. 
The role of  NK cells in autoimmune diseases is be-
ing investigated, and is highly debated as both positive 
and negative associations have been observed[96-99]. In 
the EAE model, depletion of  NK cells resulted in a 
severe relapsing EAE, and more pronounced CNS pa-
thology[100-103]. This suggests protective effects for NK 
cells, especially since the depletion was associated with 
increased CD4+ T cell activity and hence, may be associ-
ated with direct killing of  these cells[88,104]. Also in EAE, 
mice deficient in the chemokine receptor CX3CR1 had 
more severe EAE. This receptor is necessary for the re-
cruitment of  NK cells into the CNS, providing evidence 
showing that NK cell infiltrating into the CNS repre-
sents an important event in ameliorating and controlling 
the disease[105]. In the same mice there were increased 
responses from Th17 cells locally in CNS, suggesting 
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a plausible role for NK cells in curbing these cells[106]. 
Conflicting with these results, it was found that depletion 
of  NK cells in MOG-induced EAE actually ameliorated 
the disease[107]. Additionally, by stimulating NK cells to 
produce IFN-γ, these cells may also cause inflammation 
in part by stimulating Th1 cell response[108,109]. These find-
ings represent detrimental effects of  NK cells eliciting 
inflammatory lesions and exacerbating the inflammatory 
response. Much of  the confusion regarding conflicting 
findings may be attributed to failure to recognize differ-
ent effects by different subsets, which should encourage 
further investigation into this field.
The functional activity of  NK cells is variable and is 
generally lower in MS patients than in healthy individu-
als[110]. Periods of  reduced NK cell numbers in the blood 
was associated with a higher relapse tendency after. The 
same study also found a correlation between high mean 
NK cell activity and total lesion load determined by 
MRI[111]. As reduced numbers of  NK cells were thought 
to be mediated by migration into tissues including the 
CNS, this could indicate a pathological role for NK cells. 
However, it could also be viewed as a risk factor for new 
attacks due to reduced activity of  NK cells. In a more 
recent study, researchers found a reduced number of  
CD8lowCD56+CD3-CD4- cells in untreated patients with 
CIS, when compared to healthy controls[112].
Along these associations, there have been speculations 
as to how exactly NK cells mediate their effects, be it pos-
itive or negative. One suggested pathway was interactions 
between NK cells and dendritic cells[97,101]. The cognate 
and non-cognate interactions among NK cells and DCs 
have been previously described. Activated NK cells are 
also able to kill immature (i) DCs, but mature (m) DCs 
are spared. How and where these cells interact are not 
clear, but it was hypothesized that such interactions may 
occur in inflamed tissues. Our work on the effects of  GA 
on NK cells in MS patients and healthy individuals shows 
that GA influences this cross-talk between DCs and NK 
cells. Consequently, we hypothesized that this may impede 
antigen presentation to auto reactive T cells (Th17 or 
Th1), and may further reduce inflammation. We described 
that NK cells stimulated in vitro with GA became more 
cytotoxic towards autologous and allogeneic iDCs and 
mDCs[113]. Furthermore, we described how NK cells from 
EAE mice treated with GA were more cytotoxic than NK 
cells isolated from EAE mice treated with vehicle alone, 
which was associated with ameliorating the disease[114]. 
While these findings support a mechanism of  action for 
GA on NK cells, it had to be further addressed in humans 
with in vivo exposure to the drug. Consequently, we ex-
amined the activities of  NK cells and DCs in MS patients 
receiving the drug GA for one year. In this study, we com-
pared the cytotoxicity levels before treatment with those 
observed after treatment. We demonstrated that NK cells 
isolated from GA-dosed MS patients had significantly 
increased cytotoxicity against K562 tumor cells. Trends 
of  significantly increased cytotoxicity were also observed 
against both iDC and mDC in the same patients[115]. In 
summary, it seems that GA increases the cytotoxic activity 
of  NK cells when compared to pretreatment levels. The 
increased cytotoxicity correlated well with the elevated 
expression of  activating NK cells cytotoxicity receptors. 
Figure 1 represents our current knowledge regarding the 
role that NK cells might play in MS.
CONCLUSION
The evidence for a complex immunopathology has be-
come ever clearer with the reveal of  numerous genes 
associated with the immune system carrying risk of  
developing MS, novel cell subsets being discovered and 
shown to possibly be related to the pathogenesis, and 
knowledge of  how disease modifying therapies (DMT) 
target several immune cells rather than single subsets. All 
of  these call for continuous bedside-to-bench research 
into how the newer DMTs enhance, inhibit or modulate 
the immune system of  patients resulting in a better clini-
cal course than without such treatment. The introduction 
of  the new oral therapeutics teriflunomide (Aubagio®), 
fingolimod (Gilenya®) and dimethyl fumarate (Tecfidera®), 
all with incomplete understandings of  their mechanisms 
of  action on the immune system, will be particularly in-
teresting to follow in this regard.
So far, research into how immune cells act in MS 
patients, EAE models and in vitro have primarily focused 
on single subsets or categorically on either adaptive- or 
innate immune cells. Recent knowledge of  how NK 
cells may belong in a grey area between these traditional 
groupings challenges this concept[116]. For instance, while 
our own research focused on the interactions between 
NK and dendritic cells, similar interactions between NK 
and B cells would be of  interest, as B cells also have an-
tigen presenting abilities. NK cells also have the ability to 
modify or lyse T cells, and hence investigations into how 
these cells interact in MS patients or in the EAE model 
could improve our understanding of  the regulation or 
dysregulation the immune systems of  MS patients.
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